[HTML][HTML] Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
C Masuda, M Yanagisawa… - International …, 2017 - spandidos-publications.com
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), shows
superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating …
superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating …
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
C Masuda, M Yanagisawa, K Yorozu… - … Journal of Oncology, 2017 - search.proquest.com
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), shows
superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating …
superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating …
[HTML][HTML] Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
C Masuda, M Yanagisawa… - International …, 2017 - spandidos-publications.com
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), shows
superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating …
superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating …
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
C Masuda, M Yanagisawa, K Yorozu… - International Journal of …, 2017 - go.gale.com
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), shows
superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating …
superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating …
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
C Masuda, M Yanagisawa, K Yorozu… - … journal of oncology, 2017 - pubmed.ncbi.nlm.nih.gov
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), shows
superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating …
superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating …
[HTML][HTML] Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
C Masuda, M Yanagisawa, K Yorozu… - … Journal of Oncology, 2017 - ncbi.nlm.nih.gov
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), shows
superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating …
superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating …
[引用][C] Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
C Masuda, M Yanagisawa, K Yorozu… - International Journal of …, 2017 - cir.nii.ac.jp
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated
NSCLC xenograft model | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
NSCLC xenograft model | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.
C Masuda, M Yanagisawa, K Yorozu… - … Journal of Oncology, 2017 - europepmc.org
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), shows
superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating …
superior efficacy in patients with non-small cell lung cancer (NSCLC) harboring activating …